Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

BioNTech Sinks as Covid Vaccine Sales and Profit Disappoint (1)

Aug. 8, 2022, 12:37 PM

BioNTech SE dropped the most in more than three months as lagging Covid-19 vaccine orders held sales and profit short of analysts’ expectations.

Revenue in the second quarter dropped by about 40%, BioNTech said on Monday. Diluted earnings per share were 6.45 euros, below the 7.44-euro average estimate of analysts surveyed by Bloomberg.

BioNTech and partner Pfizer Inc. are counting on an omicron-adapted vaccine to reinvigorate sales for the rest of the year. The first doses of a shot tailored for both the original coronavirus and the fast-spreading omicron BA.4/5 variant should be ready in October, in time for fall ...